Significant response to pasireotide (SOM230) in the treatment of a patient with persistent, refractory Cushing's disease

Authors: Cukier, Kimberly¹; Tewari, Reena¹; Kurth, Fabian²; Schmid, Herbert A.²; Lai, Clinton³; Torpy, David J.¹

Source: Clinical Endocrinology, Volume 71, Number 2, August 2009 , pp. 305-307(3)

Publisher: Wiley-Blackwell

Document Type: Research article

DOI: http://dx.doi.org/10.1111/j.1365-2265.2008.03486.x

Affiliations: 1: Department of Endocrinology, Royal Adelaide Hospital, South Australia, Australia 2: Novartis Institute for Biomedical Research, Basel, Switzerland 3: Novartis Pharmaceuticals Australia Pty Ltd, NSW, Australia

Publication date: 2009-08-01

• In this: publication
• By this: publisher
• In this Subject: Anatomy & Physiology ,  Internal Medicine
• By this author: Cukier, Kimberly ;  Tewari, Reena ;  Kurth, Fabian ;  Schmid, Herbert A. ;  Lai, Clinton ;  Torpy, David J.

Website © Publishing Technology. Article copyright remains with the publisher, society or author(s) as specified within the article.

• Terms and conditions
• Privacy policy
• Information for advertisers